IVERIC bio (OPHT) Stock Price, News & Analysis

Company Overview

IVERIC bio, Inc. is a biopharmaceutical company which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.13 to $1.39
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 159,109 shs
• Market Capitalization: $1.65 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OPHT Stock Analysis - Frequently Asked Questions

How were IVERIC bio's earnings last quarter?

IVERIC bio, Inc. (NASDAQ:OPHT) announced its quarterly earnings results on Wednesday, October, 31st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.02.

What other stocks do shareholders of IVERIC bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IVERIC bio investors own include iShares Preferred and Income Securities ETF (PFF), Puma Biotechnology (PBYI), Incyte (INCY), Apollo Investment (AINV), BioMarin Pharmaceutical (BMRN), Meta Platforms (META) and Bristol-Myers Squibb (BMY).

Company Calendar

• Last Earnings: 10/31/2018
• Today: 4/02/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:OPHT
• CIK: 1410939
• Web: www.ophthotech.com
• Phone: (212) 845-8200
• Fax: N/A
• Employees: 35
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.67)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $63.09 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -141.53%
• Return on Assets: -41.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.09
• Quick Ratio: 10.09

Sales & Book Value

• Annual Sales: $209.98 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.00 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 41,420,000
• Free Float: N/A
• Market Cap: $1.65 billion
• Optionable: Optionable
• Beta: 1.49